1. Home
  2. CLWT vs APRE Comparison

CLWT vs APRE Comparison

Compare CLWT & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CLWT

Euro Tech Holdings Company Limited

N/A

Current Price

$1.47

Market Cap

11.3M

ML Signal

N/A

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.78

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLWT
APRE
Founded
1971
2006
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Professional and commerical equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.3M
10.8M
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
CLWT
APRE
Price
$1.47
$0.78
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $4.10
AVG Volume (30 Days)
11.6K
★ 220.9K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.22
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$17.56
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$0.55
52 Week High
$2.68
$1.69

Technical Indicators

Market Signals
Indicator
CLWT
APRE
Relative Strength Index (RSI) 32.61 47.33
Support Level $1.09 $0.59
Resistance Level $1.74 $0.81
Average True Range (ATR) 0.07 0.06
MACD -0.02 -0.01
Stochastic Oscillator 5.41 23.51

Price Performance

Historical Comparison
CLWT
APRE

About CLWT Euro Tech Holdings Company Limited

Euro Tech Holdings Co Ltd is mainly a distributor of a wide range of water treatment equipment, laboratory instruments, analyzers, test kits, and related supplies, and power generation equipment, including recorders and power quality analyzers. The Company acts as an exclusive or non-exclusive distributor for manufacturers of such equipment to commercial customers and governmental agencies in Hong Kong and mainland China, as well as commercial customers in Macau. It has two operating segments: Trading and manufacturing, which generate maximum revenue and act as a distributor of water treatment equipment, laboratory instruments, analyzers, test kits, related supplies, and power generation equipment; and the Engineering segment. The Company generates maximum revenue from the PRC.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: